Cellectis S.A. (CLLS): Price and Financial Metrics
CLLS Price/Volume Stats
| Current price | $1.51 | 52-week high | $3.38 |
| Prev. close | $1.48 | 52-week low | $1.41 |
| Day low | $1.46 | Volume | 255,700 |
| Day high | $1.59 | Avg. volume | 277,050 |
| 50-day MA | $1.82 | Dividend yield | N/A |
| 200-day MA | $2.18 | Market Cap | 83.93M |
CLLS Stock Price Chart Interactive Chart >
Cellectis S.A. (CLLS) Company Bio
Cellectis SA is a preclinical stage biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. The company was founded in 1999 and is based in Paris, France.
CLLS Price Returns
| 1-mo | -7.93% |
| 3-mo | -23.35% |
| 6-mo | -26.34% |
| 1-year | -44.89% |
| 3-year | -77.19% |
| 5-year | -90.90% |
| YTD | -16.11% |
| 2024 | -41.56% |
| 2023 | 46.67% |
| 2022 | -74.14% |
| 2021 | -69.99% |
| 2020 | 58.06% |
Continue Researching CLLS
Want to see what other sources are saying about Cellectis SA's financials and stock price? Try the links below:Cellectis SA (CLLS) Stock Price | Nasdaq
Cellectis SA (CLLS) Stock Quote, History and News - Yahoo Finance
Cellectis SA (CLLS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...